Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERIFY-2 itepekimab in moderate-to-severe COPD
2024-512012-21-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Itepekimab with Matched placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe acute exacerbation of COPD in former smokers. Started Aug 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-512012-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512012-21-00.